Three Or More Ring Hetero Atoms In The Additional Hetero Ring Patents (Class 514/236.2)
-
Publication number: 20110301164Abstract: A method is provided of treating an eye with ophthalmologically active compounds, particularly with intra-ocular pressure lowering (IOP) compounds, where a dose of 5-15 microliters is delivered at a standard concentration.Type: ApplicationFiled: August 12, 2011Publication date: December 8, 2011Inventors: BEN Z. COHEN, NIGEL KELLY
-
Patent number: 8067414Abstract: The invention provides compositions and kits comprising at least one nitric oxide enhancing prostaglandin compound or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating ophthalmic disorders; (b) treating cerebrovascular disorders; (c) treating cardiovascular disorders; (d) treating benign prostatic hyperplasia (BPH); (e) treating peptic ulcers; (e) treating sexual dysfunctions and (f) inducing abortions. The nitric oxide enhancing prostaglandin compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group.Type: GrantFiled: March 19, 2007Date of Patent: November 29, 2011Assignee: NiCox S.A.Inventor: David S. Garvey
-
Publication number: 20110281853Abstract: The present invention provides compositions and methods for treating or preventing atrial fibrillation (AF). In particular, the present invention provides administration of muscarinic receptor antagonists (e.g., M2-selective muscarinic receptor blockers), administered alone or in combination with other therapeutic agents (e.g., beta-adrenergic receptor blockers) to treat and/or prevent atrial fibrillation.Type: ApplicationFiled: May 12, 2011Publication date: November 17, 2011Inventors: Rishi Arora, David E. Zembower
-
Publication number: 20110275634Abstract: In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: January 4, 2011Publication date: November 10, 2011Applicant: THERAVANCE, INC.Inventors: Brooke Blair, Paul R. Fatheree, Melissa Fleury, Roland Gendron, Ryan Hudson, Robert Murray McKinnell, Michael Wilson
-
Publication number: 20110275635Abstract: Small molecule inhibitors of bacterial nicotinamide adenine dinucleotide synthetase (NADs), bacterial nicotinic acid mononucleotide adenylyltransferase (NaMNAT), and human nicotinamide mononucleotide adenylyltransferase (NMNAT) are provided, as well as methods of making and using the inhibitors.Type: ApplicationFiled: January 8, 2010Publication date: November 10, 2011Applicant: THE UAB RESEARCH FOUNDATIONInventors: Wayne J. Brouillette, Christie G. Brouillette, Whitney B. Moro
-
Publication number: 20110274655Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.Type: ApplicationFiled: May 5, 2011Publication date: November 10, 2011Applicant: Infinity PharmaceuticalsInventors: Adilah BAHADOOR, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
-
Publication number: 20110275617Abstract: The present invention provides an ophthalmic composition comprising a hyperbranched polymer. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polymer increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as polysorbate, hydroxypropyl methyl cellulose or hydroxyethyl cellulose, and beta-blockers, such as carteolol, levobunolol, betaxolol, metipranolol, timolol or propranolol.Type: ApplicationFiled: May 5, 2010Publication date: November 10, 2011Inventors: Jun INOUE, Tapan Shah
-
Publication number: 20110269703Abstract: A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 10, 2009Publication date: November 3, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Paul Anthony Reilly
-
Publication number: 20110269715Abstract: The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, R1 and R2 are as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound.Type: ApplicationFiled: June 2, 2011Publication date: November 3, 2011Inventors: June Chen, Simon N. Pettit, Hans G. Fliri
-
Publication number: 20110263601Abstract: Methods are disclosed for treating ulcerative colitis and related diseases and disorders, which comprise inhibiting tryptophan hydroxylase (TPH) in patients in need thereof.Type: ApplicationFiled: October 25, 2010Publication date: October 27, 2011Inventors: Philip Manton Brown, Qingyun Liu, Brian Zambrowicz
-
Patent number: 8044050Abstract: The present invention relates to derivatives of imidazo[1,2-a]azines of formula I, in which R, R1 to R3, X, Y and n have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of formula I, to pharmaceutical compositions comprising them, and to the use of compounds of formula I for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.Type: GrantFiled: August 27, 2009Date of Patent: October 25, 2011Assignee: Sanofi-AventisInventors: Gerhard Zoller, Hartmut Strobel, David William Will, Paulus Wohlfart
-
Publication number: 20110257177Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases, disorders or conditions that would benefit from inhibition of SOC channel activity.Type: ApplicationFiled: September 22, 2009Publication date: October 20, 2011Applicant: CalciMedica, Inc.Inventors: Jeffrey P. Whitten, Yazhong Pei, Kenneth A. Stauderman, Jack Roos
-
Publication number: 20110256128Abstract: The present invention provides triazole compounds of Formula I: as further described herein. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, and a method of treating a disorder mediated, at least in part, by KSP in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of Formula I.Type: ApplicationFiled: April 13, 2011Publication date: October 20, 2011Inventors: Tinya ABRAMS, Paul A. BARSANTI, Yu DING, David DUHL, Wooseok HAN, Cheng HU, Yue PAN
-
Publication number: 20110257176Abstract: A method for treating and/or ameliorating and/or preventing a disease or a disorder, the method comprising administering to an individual in need thereof at least one nitrogen heterocycle derivative of formula (I): The at least one nitrogen heterocycle derivative may also be used as a proteasome activity modulator in the manufacture of a pharmaceutical composition intended to prevent and/or treat a disease condition mediated by the proteasome activity.Type: ApplicationFiled: April 4, 2011Publication date: October 20, 2011Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE RENNES 1, UNIVERSITE PARIS DIDEROT, UNIVERSITE PIERRE ET MARIE CURIEInventors: Bruno VILLOUTREIX, Michele REBOUD-RAVAUX, Nicolas BASSE, Joelle VIDAL, Matthieu MONTES
-
Publication number: 20110251195Abstract: The invention provides a single nucleotide polymorphism (SNP) rs1042714 in the human ADRB2 gene (Gln27Glu) associated with a clinically meaningful reduction in intraocular pressure (IOP) in a human following treatment with a topical beta-blocker. Nucleic acids comprising the SNP are used to screen glaucoma-afflicted individuals to thereby provide an improved method for genotype-based prescribing of beta-blockers in glaucoma management.Type: ApplicationFiled: June 23, 2011Publication date: October 13, 2011Applicant: Marshfield ClinicInventors: Catherine Anne McCarty, James K. Burmester, Bickol N. Mukesh, Richard B. Patchett, Russell Alan Wilke
-
Patent number: 8034953Abstract: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.Type: GrantFiled: May 9, 2006Date of Patent: October 11, 2011Assignee: Incyte CorporationInventors: Andrew P. Combs, Eddy W. Yue
-
Publication number: 20110245241Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.Type: ApplicationFiled: October 8, 2010Publication date: October 6, 2011Inventors: B. Narasimhulu Naidu, Kevin Peese, Ira B. Dicker, Chen Li, Manoj Patel, Nicholas A. Meanwell, Michael A. Walker
-
Publication number: 20110245243Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cathepsin S.Type: ApplicationFiled: June 16, 2011Publication date: October 6, 2011Inventors: Hong LIU, David C. TULLY, Arnab CHATTERJEE, Phillip B. ALPER, David H. WOODMANSEE, Daniel MUTNICK
-
Publication number: 20110237511Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.Type: ApplicationFiled: June 3, 2011Publication date: September 29, 2011Applicant: Merck Frosst CanadaInventors: Xavier Billot, John Colucci, Yongxin Han, Marie-Claire Wilson, Robert N. Young
-
Publication number: 20110237587Abstract: Disclosed herein are a 1,3,5-triazine-2,4,6-triamine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for preventing or treating metabolic syndromes, diabetes, or cancers with deletion of P53 gene, which comprises the same.Type: ApplicationFiled: August 28, 2008Publication date: September 29, 2011Applicants: HANALL PHARMACEUTICAL COMPANY, LTD, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Hyae Gyeong Cheon, Kwang-Rok Kim, Sang Dal Rhee, Won Hoon Jung, Jong-Cheol Lee, Sung Wuk Kim, Sung Soo Jun
-
Publication number: 20110224187Abstract: The present invention relates to novel Pyrrolidine, Piperidine and Piperazine Derivatives, pharmaceutical compositions comprising the Pyrrolidine, Piperidine and Piperazine Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity, an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.Type: ApplicationFiled: October 14, 2009Publication date: September 15, 2011Inventors: Anandan Palani, Michael Y. Berlin, Aslanian G. Robert, Vaccaro M. Henry, Chan Tin-Yau, Xiao Dong, Degrado Sylvia, Rao U. Ashwin, Chen Xiao, Lee Yoon Joo, Sofolarides J. Michael, Shao Ning, Huang R. Ying, Liu Zhidan, Wang Li Yuan, Pu Haiyan
-
Publication number: 20110218188Abstract: The present invention relates to phenyl-pyrimidinyl-amino derivatives of formula (I) wherein Q1 and p, Ra to Rc, L1, Y, L2 and Q2 represent various substituents, their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.Type: ApplicationFiled: November 12, 2009Publication date: September 8, 2011Inventors: Christian Beier, Jurgen Benting, Isabelle Christian, Pierre-Yves Coqueron, Peter Dahmen, Ralf Dunkel, Jorg Greul, Marie-Claire Grosjean-Cournoyer, Hiroyuki Hadano, Philippe Rinolfi, Arnd Voerste, Jean-Pierre Vors, Ulrike Wachendorff-Neumann
-
Publication number: 20110212949Abstract: The present application relates to the use of heterocyclic compounds, some of which are known, for controlling animal pests, including arthropods and in particular insects, furthermore to novel heterocyclic compounds and to processes for their preparation.Type: ApplicationFiled: July 4, 2009Publication date: September 1, 2011Inventors: Thomas Bretschneider, Eva-Maria Franken, Ulrich Görgens, Martin Füßlein, Achim Hense, Joachim Kluth, Hans-Georg Schwarz, Adeline Köhler, Olga Malsam, Arnd Voerste, Angela Becker
-
Publication number: 20110206783Abstract: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.Type: ApplicationFiled: October 21, 2009Publication date: August 25, 2011Inventors: Christopher S. Burgey, Zhengwu J. Deng, Diem N. Nguyen, Daniel V. Paone, Anthony W. Shaw
-
Publication number: 20110207704Abstract: Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.Type: ApplicationFiled: August 24, 2010Publication date: August 25, 2011Applicant: ABBOTT LABORATORIESInventors: Kevin P. Cusack, Eric C. Breinlinger, Shannon R. Fix-Stenzel, Robert H. Stoffel, Kevin R. Woller, Adrian D. Hobson, Pintipa Grongsaard
-
Patent number: 8003617Abstract: The invention provides methods of treating a diabetic subject comprising administering a glucosylceramide synthase inhibitor to the subject.Type: GrantFiled: November 9, 2005Date of Patent: August 23, 2011Assignee: Genzyme CorporationInventors: Seng H. Cheng, Nelson S. Yew, Ronald K. Scheule, Hongmei Zhao
-
Publication number: 20110190255Abstract: Disclosed are compounds of Formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: August 5, 2010Publication date: August 4, 2011Inventors: John L. Gilmore, James E. Sheppeck
-
Publication number: 20110189291Abstract: Photoactivatable dendrimers and hydrogels formed therefrom include dendrimers to which polymer chains (e.g. polyethylene glycol, PEG) have been conjugated; and reactive photoactivatable groups attached to terminal functional groups of the polymer chains (e.g. hydroxyls of PEG). Exposure to a suitable wavelength of light activates the photoactivatable groups, which then crosslink with one another, thereby forming a hydrogel. The hydrogel may also include one or more agents of interest; or, in some embodiments, nanoparticles containing one or more agents of interest may be dispersed in the hydrogel. These formulations are well-suited for sustained or prolonged delivery of active agents, e.g. for the treatment of glaucoma by the sustained delivery of anti-glaucoma agents directly to the eye.Type: ApplicationFiled: February 8, 2011Publication date: August 4, 2011Inventors: Hu Yang, Pooja N. Desai, Christopher A. Holden, Uday B. Kompella, Puneet Tyagi
-
Publication number: 20110183954Abstract: The present invention relates to compounds of Formula (I): (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.Type: ApplicationFiled: December 17, 2009Publication date: July 28, 2011Applicant: ASTRAZENECA ABInventors: Lynsie Almeida, Claudio Edmundo Chuaqui, Stephanos Loannidis, Bo Peng, Mei Su
-
Publication number: 20110183953Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.Type: ApplicationFiled: November 15, 2010Publication date: July 28, 2011Inventors: Marcus F. Boehm, Esther Martinborough, Enugurthi Brahmachary, Manisha Moorjani, Junko Tamiya, Liming Huang, Adam Richard Yeager
-
Publication number: 20110178054Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.Type: ApplicationFiled: July 10, 2009Publication date: July 21, 2011Applicant: Prosidion LimitedInventors: Lisa Sarah Bertram, Matthew Colin Thor Fyfe, William Gattrell, Revathy P. Jeevaratnam, John Keily, Martin James Procter
-
Publication number: 20110177167Abstract: An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.Type: ApplicationFiled: February 7, 2011Publication date: July 21, 2011Applicant: Jagotec AGInventors: Guy Vergnault, Pascal Grenier, Lauretta Maggi, Ubaldo Conte
-
Publication number: 20110178056Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.Type: ApplicationFiled: November 15, 2010Publication date: July 21, 2011Inventors: Esther MARTINBOROUGH, Marcus F. Boehm, Adam Richard Yeager, Junko Tamiya, Liming Huang, Enugurthi Brahmachary, Manisha Moorjani
-
Publication number: 20110172202Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.Type: ApplicationFiled: November 15, 2010Publication date: July 14, 2011Inventors: Esther Martinborough, Marcus F. Boehm, Adam Richard Yeager, Junko Tamiya, Liming Huang, Enugurthi Brahmachary, Manisha Moorjani, Gregg Alan Timony, Jennifer L. Brooks, Robert Peach, Fiona Lorraine Scott, Michael Allen Hanson
-
Publication number: 20110166138Abstract: Disclosed are compounds and compositions that inhibit the action of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL), methods of inhibiting FAAH and MGL, methods of modulating cannabinoid receptors, and methods of treating various disorders related to modulation of cannabinoid receptors.Type: ApplicationFiled: March 17, 2009Publication date: July 7, 2011Inventors: Alexandros Makriyannis, Lakshmipathi Pandarinathan, Nikolai Zvonok, Teija Parkkari, Lauren Chapman
-
Patent number: 7972612Abstract: A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor having a novel action and a ?-blocker as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with the ?-blocker. For the administration mode, each drug can be administered in combination or in mixture.Type: GrantFiled: November 17, 2003Date of Patent: July 5, 2011Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Masakazu Hatano, Tadashi Nakajima, Takeshi Matsugi, Hideaki Hara
-
Publication number: 20110160186Abstract: The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the genetic polymorphism in the CYP2D6 gene.Type: ApplicationFiled: June 9, 2009Publication date: June 30, 2011Applicant: Nektar TherapeuticsInventors: Michael A. Eldon, C. Simone Jude-Fishburn, Hema Gursahani, Myong Gyong Lee
-
Publication number: 20110160196Abstract: The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat certain conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.Type: ApplicationFiled: December 22, 2010Publication date: June 30, 2011Inventors: Zhaozhong J. Jia, Yonghong Song, Robert M. Scarborough, Carroll Scarborough, Anjali Pandey
-
Publication number: 20110160154Abstract: Disclosed herein are substituted piperazine late Na+ channel modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: January 6, 2011Publication date: June 30, 2011Applicant: Auspex Pharmaceuticals, Inc.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20110158983Abstract: In alternative embodiments, this invention provides compositions and methods for treating cancer or any condition caused by dysfunctional cells, side effects from treatments for cancer or any condition caused by dysfunctional cells, e.g., mucositis therapies (e.g., for oral mucositis; digestive mucositis; esophageal mucositis; intestinal mucositis). In alternative embodiments, the invention provides cytoprotection products that may be used either alone or in combination with other medical therapies such as cancer chemotherapies and radiation therapies.Type: ApplicationFiled: March 5, 2009Publication date: June 30, 2011Inventors: Newell Bascomb, John Maki, Fredric S. Young
-
Publication number: 20110160164Abstract: The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.Type: ApplicationFiled: March 7, 2011Publication date: June 30, 2011Applicant: PTC Therapeutics, IncInventors: Jeffrey A. Campbell, Atiyya Kahn, James Takasugi, Ellen Welch
-
Patent number: 7968577Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I) an enantiomer, diastereomer, tautomer, solvate (e.g.Type: GrantFiled: October 31, 2007Date of Patent: June 28, 2011Assignee: Bristol-Myers Squibb CompanyInventors: Bingwei Vera Yang, Lidia M. Doweyko, Wayne Vaccaro, Tram N. Huynh, David R. Tortolani, T. G. Murali Dhar
-
Publication number: 20110152263Abstract: A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia. The composition contains a therapeutically effective amount of a binding-inhibiting compound selected from Compounds 1 through 15, and at least one diluent, carrier or excipient. The Compounds competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor blood type, including A, B, AB, and O blood types. The compositions can be administered to a human prior to or after infection by a Norovirus, to prevent or ameliorate an infection.Type: ApplicationFiled: November 15, 2007Publication date: June 23, 2011Inventor: Xi JIANG
-
Publication number: 20110152264Abstract: The present invention relates to an ophthalmic aqueous composition containing PGF2? analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2? analogues in an aqueous composition.Type: ApplicationFiled: May 28, 2009Publication date: June 23, 2011Applicants: Santen Pharmaceutical Co., Ltd., Asahi Glass Co., Ltd.Inventors: Timo Reunamaki, Pertti Pellinen, Olli Oksala, Kari Lehmussaari
-
Publication number: 20110150763Abstract: The invention provides for Triazine derivatives and their use to modulate protein kinase activity in a variety of conditions and diseases.Type: ApplicationFiled: December 17, 2010Publication date: June 23, 2011Applicant: ABRAXIS BIOSCIENCE, LLCInventors: Chunlin Tao, Qinwei Wang, Neil P. Desai, Patrick Soon-Shiong
-
Publication number: 20110136793Abstract: Patients which are treated with stimulants (e.g., CNS stimulants, sympathomimetic amine, or anorectic/anorexigenic), such as patients being treated for attention deficit/hyperactivity disorder or obesity, often are atrisk in developing high blood pressure. Similarly, patients which are treated with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) over an extended period of time risk developing high blood pressure. These and other iatrogenic therapies (therapies which inadvertently cause an increase in, e.g., blood pressure) are addressed by providing the patient with one or more antihypertensive drugs, most preferably calcium channel blockers, during the treatment period. The CNS or NSAIDs can be provided separately or together with the antihypertensive drugs or as part of a combined composition. The adjunctive therapy can prevent or reduces cardiovascular disease and other complications of high blood pressure attendant with these iatrogenic therapies.Type: ApplicationFiled: February 14, 2011Publication date: June 9, 2011Inventors: Peter C. Hoyle, Paul Waymack
-
Patent number: 7956054Abstract: In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: GrantFiled: July 2, 2010Date of Patent: June 7, 2011Assignee: Theravance, Inc.Inventors: Brooke Blair, Paul R. Fatheree, Melissa Fleury, Roland Gendron, Ryan Hudson, Robert Murray McKinnell, Michael Wilson
-
Publication number: 20110117158Abstract: Disclosure is provided for imidazole-triazole derivative compounds that prevent, remove and/or inhibit the formation of biofilms, compositions comprising these compounds, devices comprising these compounds, and methods of using the same.Type: ApplicationFiled: January 21, 2011Publication date: May 19, 2011Inventors: Christian Melander, Steven A. Rogers, Robert W. Huigens, III, Catherine S. Reed
-
Publication number: 20110112094Abstract: Methods of treating pulmonary hypertension are disclosed. Particular methods comprise the administration of a tryptophan hydroxylase inhibitor and a prostacyclin. Pharmaceutical formulations are also disclosed.Type: ApplicationFiled: January 14, 2011Publication date: May 12, 2011Inventor: Arthur T. Sands
-
Publication number: 20110105483Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to the use of a substituted triazole compound of the invention, or a composition comprising such a compound in the preparation of a medicament for preventing or treating hyperprolif erative disorders, such as cancer, in a subject in need thereof.Type: ApplicationFiled: February 8, 2008Publication date: May 5, 2011Inventors: Dinesh U. Chimmanamada, Joseph A. Burlison, Weiwen Ying, Lijun Sun, Stefan Michael Schweizer, Shijie Zhang, Zachary Demko, David James, Teresa Przewloka